TP53 and acute myeloid leukemia: Both TP53 wild-type and mutant AML cells presented significant increases in TP53 mRNA (SKM1: control vs 0.5 μM cytarabine,P < 0.01; THP1: control vs cytarabine,P < 0.05; MV4-11: control vs cytarabine,P < 0.05; and MOLM-13: control vs cytarabine,P < 0.05) and protein expression levels after treatment with cytarabine (Figure 1B,C).